Reviva Pharmaceuticals Holdings
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. over the previous period. Total operating expenses were $39,503,636,000,000.
Profit Margin
| 2020 | 0 | -3.78M | |
|---|---|---|---|
| 2021 | 0 | -8.52M | |
| 2022 | 0 | -24.33M | |
| 2023 | 0 | -39.26T |
RVPHW Income Statement (2020 – 2023)
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
Revenue | ||||
Revenue | 0 | 0 | 0 | 0 |
Cost of revenue | 0 | 0 | 0 | 724.74K |
Gross profit | 0 | 0 | 0 | -724.74K |
Operating exp. | ||||
Research and development | 31.41T | 18.94M | 4.85M | 295.15K |
Selling and marketing | 0 | 0 | 0 | 0 |
Total operating expenses | 39.50T | 24.30M | 10.10M | 2.43M |
Operating income | -39.50T | -24.30M | -10.10M | -2.43M |
Other income (expenses), net | 39.50T | -11.90K | 1.58M | -1.34M |
Income before tax | -39.24M | -24.31M | -8.51M | -3.78M |
Income tax expense | -16.94B | 20.77K | 6.00K | 800 |
Net income | -39.26T | -24.33M | -8.52M | -3.78M |
Earnings per share | ||||
Basic EPS | -1.65 | -1.25 | -0.58 | -1.24 |
Diluted EPS | -1.65 | -1.25 | -0.58 | -1.24 |
| Data source | Data source | Data source | Data source |